FDA Clears Aperio’s Digital Pathology System

CEO SUMMARY: In May, the FDA announced clearance for Leica Biosystems to market its Aperio AT2 DX System for clinical diagnosis in the United States. The Aperio AT2 DX System is intended for in vitro diagnostic use as an aid to pathologists reviewing and interpreting digital images of surgical pathology slides prepared from formalin-fixed paraffin …

FDA Clears Aperio’s Digital Pathology System Read More »

To access this post, you must purchase The Dark Report.

FDA Clears Aperio’s Digital Pathology System

Agency says digital pathology whole-slide imaging system is substantially equivalent to Philips’ device

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month